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Abstract: Nucleic Acid Therapeutics (NATs), including siRNAs and AntiSense Oligonucleotides
(ASOs), have great potential to drug the undruggable genome. Targeting siRNAs and ASOs to specific
cell types of interest has driven dramatic improvement in efficacy and reduction in toxicity. Indeed,
conjugation of tris-GalNAc to siRNAs and ASOs has shown clinical efficacy in targeting diseases driven
by liver hepatocytes. However, targeting non-hepatic diseases with oligonucleotide therapeutics
has remained problematic for several reasons, including targeting specific cell types and endosomal
escape. Monoclonal antibody (mAb) targeting of siRNAs and ASOs has the potential to deliver these
drugs to a variety of specific cell and tissue types. However, most conjugation strategies rely on
random chemical conjugation through lysine or cysteine residues resulting in conjugate heterogeneity
and a distribution of Drug:Antibody Ratios (DAR). To produce homogeneous DAR-2 conjugates with
two siRNAs per mAb, we developed a novel two-step conjugation procedure involving microbial
transglutaminase (MTGase) tagging of the antibody C-terminus with an azide-functionalized linker
peptide that can be subsequently conjugated to dibenzylcyclooctyne (DBCO) bearing oligonucleotides
through azide-alkyne cycloaddition. Antibody-siRNA (and ASO) conjugates (ARCs) produced using
this strategy are soluble, chemically defined targeted oligonucleotide therapeutics that have the
potential to greatly increase the number of targetable cell types.
Keywords: oligonucleotide therapeutics; siRNA; antisense oligonucleotides; monoclonal antibodies;
antibody-siRNA conjugate (ARC); microbial transglutaminase; copper-less click
1. Introduction
Nucleic Acid Therapeutics (NATs), including siRNAs and AntiSense Oligonucleotides (ASOs),
are a powerful class of therapeutics that have the potential to treat diseases that are refractory or
undruggable by small molecule therapeutics and monoclonal antibody (mAb) therapeutics. However,
due to their chemical composition of a highly charged phosphate backbone and macromolecular weight
of ~6000 to ~14,000 Daltons (Da), delivery of NATs remains problematic [1]. Furthermore, naked
siRNAs display poor pharmacokinetics, poor cellular uptake and poor endosomal escape [1], all of
which highly restrict NATs to selective tissue types and subclasses of oligonucleotides. One strategy to
address these problems is to protect and deliver siRNAs via formulation within lipid nanoparticles
(LNPs) [2]. However, this approach suffers from increased toxicity and a low or poor diffusion
coefficient. More recently, chemical conjugation of siRNA and ASO oligonucleotides to targeting
domains has enabled binding to and cellular uptake in a limited number of therapeutically relevant cell
types. For example, oligonucleotides bearing tris-GalNAc moieties that target the asialoglycoprotein
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receptor (ASGPR) on liver hepatocytes have shown significant successes in multiple clinical trials [3–5].
These encouraging results show the path forward for the targeted delivery of NATs to other, non-hepatic
tissues [6].
mAbs are a highly attractive platform for generating targeted oligonucleotide therapeutics.
Antibody-Drug conjugates (ADCs) are a clinically proven versatile means to specifically target highly
cytotoxic payloads to numerous cancer cell types, thereby improving the therapeutic index of promising
anticancer toxic agents [7–9]. Early ADC conjugation approaches utilized the surface amino group of
lysine residues, resulting in variable DARs [10,11]. Full size mAbs possess approximately 40 reactive
lysines, resulting in the potential of ~780 regioisomers for a DAR-2, 10,000 for a DAR-3 and >90,000 for
a DAR-4 [12]. A representative ADC with an average DAR between 2–3 exhibits variable individual
DARs from 0 to 6 or more, each with a highly different pharmacokinetic (PK) profile, as high DARs
drive rapid blood clearance likely due to hydrophobicity [13,14]. Reduction of cysteine disulfides
and conjugating the toxic drug to free sulfhydryls improved ADCs by conjugating drugs distal to
antigen binding sites and limiting the DAR range between 0 and 8 [15,16]. However, the advent of
site selective conjugation has shown dramatic improvements in the generation of consistent ADC
DARs, and, consequently, PK and pharmacodynamic (PD) properties in preclinical models [12,13,17]
and clinical trials [18,19]. Site selective conjugation in the generation of ADCs can be performed
by several means, either enzymatic or chemical crosslinking. We favor the enzymatic Microbial
Transglutaminase (MTGase) approach [20] that has been used to generate DAR-2 specific ADCs [21].
This approach requires the genetic insertion of a glutamine conjugation handle into the mAb coding
sequence [21]. MTGase, an inexpensive and highly efficient bacterial enzyme involved in cell wall
production, crosslinks proteins by catalyzing the formation of isopeptide bonds between the amino
group of lysine and amide group of glutamine residues [20].
Here, we describe a simple conjugation procedure for the production of DAR-2 chemically defined,
antibody-siRNA conjugates (ARCs). We utilized MTGase to add a bi-functional Lysine-Azide linker to
mAb through heavy chain C-terminal glutamine genetic tags. siRNAs were conjugated to mAb-Linker
peptides via Copper-free strain-promoted azide-alkyne cycloaddition (SPAAC) click conjugation,
then purified by size exclusion chromatography (SEC) to obtain ARCs with no MTGase or siRNA
contaminants. Thus, the MTGase conjugation approach allows for a rapid and quantitative site selective
conjugation of oligonucleotides (siRNAs, ASOs, etc.) to mAbs to generate ARCs.
2. Results
2.1. Generation of MTGase Engineered mAbs
To test MTGase conjugation of mAbs, we first engineered the cDNA of an anti-CD33 IgG4 clinical
mAb [7] to contain the MTGase conjugation tag. Synthetic cDNAs encoding the light and heavy
chain variable domains were cloned upstream of the appropriate immunoglobulin constant regions
(Kappa light chain, IgG4 heavy chain) into pCDNA3.1 expression plasmids. The MTGase conjugation
handle, LLQGA [21], was inserted into the C-terminus of the heavy chain, followed by a translational
termination. Suspension ExpiCHO-S cells were transfected with expression plasmids containing heavy
chain and light chain cDNAs, incubated overnight at 37 ◦C, then placed at 32 ◦C for 10-14 days for mAb
production [22]. To purify the tagged anti-CD33 mAb, cells were pelleted and culture supernatant was
filtered and passed through a Protein A chromatography column followed by SEC. This approach
typically yields 5 to 20 mg of purified mAb per 35 mL of culture media.
To determine the efficiency of MTGase conjugation, the degree of off-target conjugation and
whether MTGase conjugation interferes with antibody specificity, we MTGase labeled the engineered
anti-CD33 mAb with a Lysine-bearing fluorescent peptide, KAYA-PEG6-K-Fluorescein (KF) (Figure 1a).
Following a 1 hr incubation at room temperature of a 1:5 molar ratio of mAb to KF peptide with
3.15 U/mL MTGase, SDS-PAGE analysis revealed a single heavy chain species of increased molecular
weight (Figure 1b), consistent with a quantitative conjugation of one peptide per heavy chain or
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2 per mAb. Gel imaging of fluorescein fluorescence produced signal overlapping with the conjugated
heavy chain with no non-specific labeling of the light chain (Figure 1c). Furthermore, consistent with the
formation of a single heavy chain conjugate, we did not detect any high molecular weight heavy chain
to light chain, heavy chain to heavy chain or inter-mAb conjugation species. To determine whether
modified mAb-KF retained target specificity, we stained CD33-positive acute myeloid leukemia THP1
cells and CD33-negative acute T cell leukemia Jurkat cells and performed flow cytometry analysis.
The mAb-KF conjugate stained CD33-positive THP1 cells, but not CD33-negative Jurkat cells in a
dose-dependent fashion, demonstrating that MTGase-mediated KF conjugation did not alter anti-CD33
mAb specificity (Figure 1d).
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Figure 1. MTGase site specifically labels engineered anti-CD33 Ab. (a) Structure of mAb-KF peptide
conjugate. Conjugated lysine is highlighted in blue and fluorescein is highlighted in green; (b)
UV protein stained SDS-PAGE gel of unconjugated mAb and mAb-KF. Molecular weight markers
are in kilodaltons (kDa). HC—heavy chain, LC—light chain, HC-KF—heavy-chain-KF conjugate,
MTGase—microbial transglutaminase; (c) FITC epifluorescence image of the same SDS-PAGE gel.
KF—free KF peptide; (d) Flow cytometry of mAb-KF stained THP1 (CD33-positive) and Jurkat
(CD33-negative) cells. Following spin column cleanup, mAb-KF conjugate was directly diluted in
stain buffer at the indicated ratios: blue—1:10,000, green—1:1,000, orange—1:100. Unstained cells are
represented in gray. All plots are represented as percent maximum cell count.
2.2. MTGase Generation of ARCs
To conjugate siRNAs to the engineered mAb, we synthesized a bi-functionalized Lysine-Azide
linker peptide, K-PEG6-SG-K-N3 (KN3) (Figure 2a). The KN3 linker peptide allows for MTGase
conjugation to the engineered anti-CD33 mAb via the lysine amino group and copper-free DBCO click
conjugation to siRNAs via the azide group [23]. Similar to MTGase conjugation of the KF peptide
above (Figure 1), a 1:5 molar ratio of mAb to KN3 peptide with 3.15 U/mL MTGase for 1 hr at room
temperature resulted in near complete and selective conjugation of KN3 peptide to the anti-CD33 mAb
heavy chain (Figure 2b). To separate conjugated mAb from MTGase and free linker peptide, we ran
Molecules 2019, 24, 3287 4 of 13
the reaction over a SEC column (Figure 2c). SEC cleanly separated all three molecules and allowed for
isolation of the mAb-linker peptide conjugate in 4 fractions (Figure 2d).
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Figure 2. Conjugation and purification of mAb-KN3 conjugate. (a) Structure of mAb-KN3 peptide
conjugate. Conjugated lysine is highlighted in blue and conjugatable azidolysine is highlighted
in red; (b) UV protein stained SDS-PAGE gel of unconjugated mAb and mAb-KN3. Molecular
weight markers are in kilodaltons. HC—heavy chain, LC—light chain, HC-KN3—heavy-chain-KN3
conjugate, MTGase—microbial transglutaminase; (c) SEC analysis of the crude mAb-KN3 conjugation
reaction. mAb-KN3 – soluble mAb-KN3 conjugate, MTGase—microbial transglutaminase enzyme,
Peptide—unconjugated KN3 peptide. (d) SEC purification of mAb-KN3 conjugate. Gray boxes indicate
the elution volumes of collected fractions (6–9).
Using a 5’ DBCO TEG linked phosphoramidite [24], we next synthesized an siRNA with a
DBCO group on the 5’ end of the passenger strand for copper-free click conjugation (Figure 3a).
To form a double stranded siRNA, the DBCO passenger strand was duplexed 1:1.1 with a guide
strand. To generate an ARC, the DBCO-siRNA was incubated overnight with the purified mAb-KN3
conjugate in PBS + 40 mM L-Arginine at 37 ◦C. SEC analysis demonstrated that soluble ARC elutes
separately from excess DBCO-siRNA (Figure 3b) and are primarily present in three fractions (Figure 3c).
SDS-PAGE analysis showed a near complete conversio of h avy chain-KN3 conjugate to heavy
chain-KN3-siRNA conjugate (F gure 3d). Importantly, we did not detect any off-target MTGase or
DBCO conjug tion to the light ch in (Figure 3d). In addition, the heavy hain-KN3-siRNA conjugate
displayed an appar nt mol cular weight shift of approximately 15 kDa, c sistent with conjugation of
1 siRNA duplex per heavy chain, indicating the site selective generation of DAR-2 ARCs.
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Figure 3. Conjugation and purification of ARC. (a) Structure of mAb-KN3-DBCO-TEG-siRNA conjugate.
Conjugated lysine is highlighted in blue. Conjugated triazole (azidolysine origin) is highlighted in
red. Conjugated DBCO moiety is highlighted in green; (b) SEC analysis of the crude ARC conjugation
reaction. UV absorbance at 260 nm is traced in red and absorbance at 280 nm is traced in blue;
(c) SEC purification of ARC. Gray boxes indicate the elution volumes of collected fractions (5–7);
(d) UV protein stained SDS-PAGE gel of unconjugated mAb, mAb-KN3 and ARC. Molecular weight
markers are in kilodaltons. HC—heavy chain, LC—light chain, HC-KN3—heavy-chain-KN3 conjugate,
HC-KN3-siRNA–heavy-chain-KN3-siRNA conjugate.
2.3. ARC Binding to CD33-Positive Cells
Conjugation of molecules to mAbs can alter their binding avidity [25–28]. To ensure that our
site selective siRNA conjugation approach to the C-terminus of the heavy chain did not interfere
with binding, we treated CD33-positive THP1 cells and assayed for binding by FACS (Figure 4).
Both anti-CD33 mAb and the purified anti-CD33 ARC avidly and essentially equally bound THP1 cells.
In contrast, treatment with the control FITC labeled anti-human secondary antibody only showed
a minor increase above untreated cells. These observations demonstrate the ability of site selective
siRNA conjugation to generate a DAR-2 ARC that retains all of the antigen binding avidity of the
parent un-conjugated mAb.
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Figure 4. ARC Bindi g to THP1 Cells. Flow cytometry of mAb and ARC stained THP1 (CD33-positive)
cells. Following SEC purification, mAb/ARC were applied to cells at 25 nM in FACS buffer. Secondary
FITC labeled antibody was diluted 1:200 in FACS buffer. Unstained cells are represented in gray.
Secondary FITC labeled antibody only is a solid black line. Anti-CD33 mAb is represented by a blue
line. Anti-CD33 ARC is represented by a red line. All plots are represented as percent maximum
cell count.
3. Discussion
NATs, including siRNAs and ASOs, have the potential to transfor edicine for the treat ent of
a wide array of diseases, including cancer, pandemic influenza, and Alzheimer’s Disease. However,
targeting and intracellular delivery remain the two main challenges to overcome to achieve this
potential [1]. While LNP encapsulation has enabled delivery of siRNAs to the liver, due to their poor
PK and diffusion coefficients, the NAT field is moving away from LNPs and toward single molecule,
targeted conjugates. For liver diseases, the stand out tris-GalNAc targeting domain to deliver siRNAs
and ASOs to liver hepatocytes is already showing significant benefit for patients in clinical trials [3–5].
While the success of GalNAc conjugates has inspired a gold rush of companies striving to develop
liver-targeted therapies, it also raises the possibility of successfully targeting oligonucleotide therapies
to extra-hepatic tissues. Through the exquisite specificity of mAbs, ADCs have already been shown
to target chemical payloads to myriad cancer cell types. Early ADC approaches were assembled
through random chemical conjug tion that can impair PK a d cl arance [13,29]. To avoid the pitfalls
of random ch mical conjugation, the newest gener tion of ADCs ave been designed to use site
selective conjugation approach that place the payload at specific locat ons with a fixed DAR number,
resulting in consistent PK and manufacturing profiles [12]. We appli d these l sso s into the design
principles of ARCs. First, ARCs utilize a genetically engineered MTGase conjugation handle inserted
into the C-terminus of the heavy chain. This results in a near quantitative MTGase conjugation of
the bi-functional KN3 linker peptide to C-termini of both heavy chains. MTGase is efficient, and as
a product of the food industry it is easily purchased in large (kilogram) quantities for low cost and
therefore highly scalable. High yield production in E. coli has also recently been reported, bringing
down the cost of in-house production [30] and paving the way for GMP MTGase. Second, copper-free
click conjugation of DBCO-siRNAs to mAb-KN3 linker peptide results in a highly efficient (>90%)
conjugation. Together, these methods result in the consistent lot-to-lot generation of DAR-2 ARCs that
does not interfere with mAb binding and has a predicted consistent PK profile.
A potential pitfall in any conjugation strategy is off-target conjugation resulting in product
heterogeneity. There are multiple glutamine and lysine residues present on the surface of monoclonal
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antibodies; however, MTGase reactivity depends upon preferred glutamine substrate properties,
neighboring residues and solvent accessibility. Limiting the MTGase units and time of the reaction
results in on-target site selective conjugation. While we have observed higher order conjugate bands,
these were driven by excessively high concentrations of MTGase with overnight incubation periods.
By contrast, the optimized parameters discussed here result in the consistent generation of DAR-2
ARCs free from off-target conjugations, suggesting that there is a relatively wide window for on-target
conjugation vs. off-target conjugation.
Despite the availability of relatively inexpensive alkyne phosphoramidites that can be used
for copper-catalyzed cycloaddition, we selected a DBCO-bearing passenger strand for SPAAC to
avoid the use of copper. Oligonucleotides must be chemically stabilized for successful systemic
delivery [31,32] and the inclusion of phosphorothioate (PS) backbone linkages is critical for protecting
oligonucleotides from nucleases and improving potency by several fold [33]. Divalent metal ions, such
as copper, can promote desulfurization (oxidation) of PS linkages [34]. We have observed changes in
oligonucleotide mass consistent with this phenomenon following treatment with copper(II) sulfate and
sodium ascorbate (data not shown). To avoid loss or variation of oligonucleotide potency, we therefore
selected DBCO as the alkyne for cycloaddition to synthesize ARCs. In this work we demonstrate
efficient conjugation of DBCO-siRNA to azide-functionalized mAb-KN3 using a low molar ratio,
indicating that this approach can be successfully used to produce defined ARCs without the drawbacks
of copper-catalyzed click.
We have demonstrated the production of uniform ARCs with a DAR of 2, but our approach could
be used to produce uniform ARCs with higher or lower DARs as well. By incorporating MTGase tags
on mAb light chains, a DAR of 4 can be attained [21]. To generate ARCs with a DAR of 1, a monovalent
binder format such as Fab or scFv could be used. Furthermore, full-size mAbs engineered with
“knobs-into-holes” heterodimeric heavy chains [35] that incorporated an MTGase tag on only one
chain, but not the other, could be used to produce homogeneous DAR-1 ARCs. The ability to produce
uniform defined ARCs is beneficial in many ways. Importantly, it allows optimization of parameters
that are difficult to control otherwise, especially the placement of the siRNA cargo. It has been shown
that conjugation site plays an important role in ADC efficacy and pharmacokinetics in vivo [36] and
therefore, it is reasonable to assume that the same may be true for ARCs. Furthermore, defined
placement of cargo results in lower batch-to-batch variation and streamlines the purification process
by eliminating the need to remove over- or under-conjugated material. Overall, this rapid, simple,
and efficient strategy is an important step toward delivering oligonucleotide therapies to extrahepatic
tissues. Future studies are focused on (1) whether or not the linker between the mAb and siRNA needs
to be cleavable in the endosome prior to endosomal escape, which is the case for most ADCs [10], and
(2) endosomal escape of the siRNA into the cytoplasm, which is the rate-limiting delivery step for
achieving RNAi activity [1].
4. Materials and Methods
4.1. Peptide Sequences and Synthesis
KF peptide sequence: KAYA-PEG6-K-fluorescein; KN3 peptide sequence: K-PEG6-SG-N3.
Peptides were synthesized at 25 µmol scale on rink-amide MBHA solid support using Fmoc solid phase
chemistry on a Symphony Quartet peptide synthesizer (Rainin Instruments, Protein Technologies, Inc.
Woburn, MA, USA) utilizing standard protected amino acids and coupling reagents (Novabiochem,
Laufelfingen, Switzerland), as well as specialty residues 5(6)-carboxyfluorescein (Sigma-Aldrich,
St. Louis, MO, USA), Fmoc-lys (IVDDE)-OH and 5-azidopentanoic acid (Chem-Impex International,
Wood Dale, IL, USA). For synthesis of KF, after the N-terminal final fmoc removal and capping
(acetylation) (1:1:2 acetic anhydrous, DIPEA, DMF), the column was washed sequentially with DMF,
DCM, DMF. ivDde was removed from the side chain of the C-terminal lysine by incubating in
2% hydrazine in DMF 2 × 15 min, followed by washing and coupling to 5(6)-carboxyfluorescein.
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For synthesis of KN3, after the N-terminal final fmoc removal and capping (acetylation) (1:1:2 acetic
anhydrous, DIPEA, DMF), the column was washed sequentially with DMF, DCM, DMF. ivDde was
removed from the side chain of the C-terminal lysine by incubating in 2% hydrazine in DMF 2 × 15 min,
followed by washing and coupling to 5-Azidopentanoic acid. Peptides were cleaved and deprotected
using standard conditions (95.0% TFA, 2.5% water, 2.5% TIS) for 2 h. Crude peptides were precipitated
with cold diethyl ether and purified by RP-HPLC on a 1200 Series HPLC (Agilent Technologies,
Santa Clara, CA, USA) with a Prep C18 30 × 250 mm column (Agilent Technologies). Fractions with
absorbance at 230 nm were analyzed by MALDI-TOF with α-CHCA matrix on a DE Voyager Pro
(Applied Biosystems, Foster City, CA, USA). Fractions with the correct mass (KF—observed mass:
1313, calculated mass: 1313; KN3—observed mass: 905, calculated mass 920) were pooled, lyophilized,
resuspended at 25 mM in pure water and stored at −20 ◦C.
4.2. Oligonucleotide Sequences and Synthesis
Sense oligonucleotide: 5′-DBCO-TEG-AGAAGAUGCUUCAGACAGAUT-3′; Antisense
oligonucleotide: 5′-UCUGUCUGAAGCAUCUUCUUT-3′. Purines (A, G) were modified with 2′
O-methyl ribose and pyrimidines (C, U) were modified with 2′ F ribose. Both oligonucleotides retain
deoxy-T on the 3′ end following cleavage from the CPG support. Oligonucleotides were synthesized
on a MerMade 6 oligonucleotide synthesizer (Bioautomation, Irving, TX, USA) using commercially
available phosphoramidites (Carbosynth LLC, San Diego, CA, USA; Glen Research, Sterling, VA, USA)
according to manufacturer’s recommendation on Glen dT-Q-CPG 500 support (Glen Research) and
deprotected by treatment with 10% diisopropylamine (DIA) in methanol 4 hr at room temperature.
Oligonucleotides were purified by RP-HPLC on a 1200 Series HPLC (Agilent Technologies) with a
Zorbax SB-C18 column (Agilent Technologies). Oligonucleotides were eluted with a linear gradient
of acetonitrile and fractions with absorbance at 260 nm were analyzed by MALDI-TOF with THAP
matrix on a DE Voyager Pro (Applied Biosystems) as well as by denaturing gel electrophoresis in
methylene blue stained polyacrylamide-urea gels (15% acrylamide, 7M Urea). Fractions containing
peaks with the correct mass (Sense strand-observed mass: 7948, calculated mass: 7958; Antisense
strand—observed mass 6650, calculated mass 6659) were pooled, lyophilized, and resuspended at
500 nM in 50:50 acetonitrile:water.
4.3. Monoclonal Antibody Production and Purification
The variable regions of a monoclonal anti-CD33 antibody (hP67.6) were synthesized as gBlocks
(IDT) and seamlessly cloned into expression plasmids in frame with sequences encoding the appropriate
constant regions (homo sapiens IgG4 heavy chain constant region and homo sapiens kappa light chain
constant region) using InFusion® HD Reagent (Takara Bio USA, Mountain View, CA, USA). The heavy
chain terminal lysine residue was replaced with LLQGA by PCR-mediated mutagenesis. All antibody
coding sequences were confirmed by Sanger sequencing. Plasmids were transfected in ExpiCHO-S
cells (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s recommendation
for a 30 mL culture size in a 125 mL polycarbonate vent cap flask (Thermo Fisher Scientific) at a mass
ratio of 4:1 for heavy chain and light chain plasmids. Cells were incubated overnight in a humidified
37 ◦C incubator with 8% CO2 on a shaking platform set to 140 RPM. The following day, cells were
treated with ExpiFectamine CHO Enhancer (Thermo Fisher Scientific) and ExpiCHO Feed (Thermo
Fisher Scientific) according to the manufacturer’s recommendation and transferred to a humidified
32 ◦C incubator with 5% CO2 on a shaking platform set to 140 RPM. 5 days after transfection, additional
ExpiCHO Feed was added according to the manufacturer’s recommendation. Antibody was harvested
12 days after transfection. Briefly, the cell suspension was centrifuged at 200× g for 5 min at 4 ◦C in a
50 mL conical tube. The first supernatant was collected in a clean 50 mL conical tube and centrifuged
again at 5000× g for 30 min at 4 ◦C. The second supernatant was filtered sequentially through 0.45 µm
and 0.22 µm PVDF syringe filters. Antibody was isolated from clarified supernatant by Protein A
Molecules 2019, 24, 3287 9 of 13
affinity chromatography and further purified and buffer exchanged by SEC in phosphate buffered
saline. Antibody concentration was determined by BCA Protein Assay (Thermo Fisher Scientific).
4.4. MTGase Conjugation
10×MTGase enzyme buffer was prepared (Sodium Chloride 500 mM, Sodium Acetate 500 mM,
pH 5.8) and a working aliquot was diluted 10-fold to 1× in water. Activa MTGase enzyme (Ajinomoto
North America, Inc., Itasca, IL, USA) was reconstituted in 1× MTGase enzyme buffer to achieve a
working concentration of 63 mg/mL (12.6 Units/mL). 10×MTGase reaction buffer was prepared (NaCl
1.5 M, Tris-HCl pH 8.0 250 mM). The reaction was set up as follows in a 1.5 mL microcentrifuge tube:
10×MTGase reaction buffer equivalent to 1/10th the final reaction volume was added. MilliQ water was
used to adjust the final volume. MTG-tagged antibody was added to a final concentration of 6.5 µM.
Lys-bearing peptide was added to a final concentration of 65 µM (5:1 molar excess relative to the 2
conjugatable MTG sites on each antibody). MTGase was added to a final concentration of 3.15 U/mL.
The reaction was mixed well by pipetting and incubated on a rotisserie at room temperature for one
hour. Conjugation efficiency was analyzed by electrophoresis on a 10% SDS-PAGE gel (150 V, 70 min),
followed by staining with Blazin’ Bright™ Luminescent UV Protein Gel Stain (Gold Biotechnology,
St. Louis, MO, USA) and imaging on a UV transilluminator. Fluorescein was imaged before staining
using an epifluorescence imager with an Alexa 488 filter.
4.5. Azide-Alkyne Click Conjugation
DBCO-bearing sense strand oligonucleotide was mixed and duplexed with 1.1 equivalents of
antisense strand (to eliminate un-duplexed sense strand) by heating to 65 ◦C for 3 min, cooling to 22 ◦C,
and holding for 3 min, followed by cooling to 4 ◦C. The amount of duplex for a ratio of 2.5:1 relative to
mAb-KN3 peptide (2 per mAb) was dried down by vacuum evaporation and resuspended to a final
concentration of 333 µM with mAb (67 µM) in phosphate buffered saline and l-Arginine (40 mM).
The reaction was incubated at 37 ◦C for 16 h. Conjugation efficiency was analyzed by electrophoresis
on a 10% SDS-PAGE gel (150 V, 70 min), followed by staining with Blazin’ Bright™ Luminescent UV
Protein Gel Stain (Gold Biotechnology) and imaging on a UV transilluminator.
4.6. FPLC Purification of Conjugates
Crude conjugation reactions were purified by SEC using a BioLogic FPLC (Bio-Rad, Hercules, CA,
USA) and a SEC650 10 × 300 gel filtration column (Bio-Rad) equilibrated in PBS with a flow rate of
1.8 mL/min. Absorbance at 230, 260 and 280 nm was measured and 0.5 mL fractions were collected
across all significant peaks. The highest purity fractions were pooled and concentrated using Amicon
spin filters, 30 kDa MWCO (Millipore, Burlington, MA, USA) and quantified by BCA protein assay
(Thermo Fisher Scientific).
4.7. Cell Culture
THP1 and Jurkat cells were grown in RPMI (Thermo Fisher Scientific) supplemented with 10% Fetal
Bovine Serum (Sigma-Aldrich) and Penicillin/Streptomycin (Thermo Fisher Scientific) in a humidified
37 ◦C tissue culture incubator with 5% CO2 atmosphere. Cells were split when culture density reached
approximately 8.0 × 105/mL by centrifuging a portion of the culture at 200× g for 3 min, aspirating
the spent medium and resuspending the cells to a final density of 2.0 × 105/mL. ExpiCHO-S cells
(Thermo Fisher Scientific) were cultured in ExpiCHO Expression Medium (Thermo Fisher Scientific) in
a humidified 37 ◦C tissue culture incubator with 8% CO2 atmosphere. 30 mL cultures were grown in
125 mL vented shaker flasks (Thermo Fisher Scientific) on an orbital shaker set to 140 rpm. Cells were
split when density reached approximately 5.0 × 106/mL by taking an aliquot of cells and diluting it to
between 1.0 × 105–3.0 × 105 cells/mL with fresh pre-warmed culture medium.
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4.8. Cell Staining and Flow Cytometry
For each condition tested, 1.0 × 105 cells were pelleted in a microcentrifuge tube at 200 × g for
3 min and the supernatant was removed by pipetting. All subsequent steps were carried out on ice
with ice-cold solutions. Pellets were resuspended in 100 µL of FACS buffer (PBS, BSA 1 mg/mL, EDTA
5 mM) and pelleted again. The supernatant was removed, cells were then resuspended in mAb-KF at
the indicated concentrations, and incubated on ice under foil for 30 min with gentle mixing by flicking
the tube every 10 min. Cells were pelleted again and stain was removed by pipetting. Cells were
washed 3× by resuspending in 100 µL FACS buffer, pelleting, and aspirating. Cells were resuspended
in 350 µL FACS buffer and strained through nylon mesh into clean FACS tubes on ice. Cells were
assayed for fluorescein signal by flow cytometry on an LSR II (BD Biosciences, Franklin Lakes, NJ, USA)
and histograms were plotted using FlowingSoftware (http://flowingsoftware.btk.fi/) and FlowJoTM
(FlowJo LLC, Ashland, OR, USA). For ARC binding, mAb and ARC were diluted to 25 nM in FACS
buffer. THP1 cells were stained with mAb or ARC as described above and washed as described above.
Goat anti-Human-FITC secondary antibody (Thermo Fisher Scientific) was diluted 1:200 in FACS
buffer and applied to cells in the same manner followed by washes as described above. Staining was
assayed for FITC signal by flow cytometry, as described above.
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Abbreviations
α-CHCA Alpha-Cyano-4-Hydroxycinnamic Acid
ADC Antibody-Drug Conjugate
ARC Antibody-siRNA Conjugate
ASGPR Asialoglycoprotein Receptor
ASO Antisense Oligonucleotide
DAR Drug-Antibody Ratio
DBCO Dibenzylcyclooctyne
DCM Dichloromethane
DIA Diisopropylamine
DIPEA N,N-Diisopropylethylamine
DMF Dimethyl Formamide
EDTA Ethylenediaminetetraacetic Acid
FACS Fluorescence Activated Cell Sorting
FITC Fluorescein Isothiocyanate
FPLC Fast Protein Liquid Chromatography
GalNAc N-Acetylgalactosamine
GMP Good Manufacturing Practice
HC Antibody Heavy Chain
kDa Kilodalton
KF KAYA-PEG6-K-Fluorescein
KN3 K-PEG6-SG-K-N3
LC Antibody Light Chain
LNP Lipid Nanoparticle
mAb Monoclonal Antibody
MALDI-TOF Matrix Assisted Laser Desorption Ionization Time-of-Flight
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MTGase Microbial Transglutaminase
MWCO Molecular Weight Cutoff
NATs Nucleic Acid Therapeutics
PBS Phosphate Buffered Saline
PCR Polymerase Chain Reaction
PD Pharmacodynamic
PK Pharmacokinetic
PS Phosphorothioate
RP-HPLC Reverse Phase High Performance Liquid Chromatography
SDS-PAGE Sodium Dodecylsulfate Polyacrylamide Gel Electrophoresis
SEC Size Exclusion Chromatography
siRNA Small Interfering Ribonucleic Acid
SPAAC Strain-Promoted Azide-Alkyne Cycloaddition
TEG Triethylene Glycol
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